Business risk concept

Barron’s writes:

Johnson & Johnson’s Covid-19 vaccine offers enormous promise as a pathway out of the worst of the pandemic. Delivered as a single dose, without the extreme storage requirements of the vaccines from Pfizer and Moderna, it could speed up global inoculation if it proves effective.

But on Wednesday, the New York Times reported that the company is facing delays in the manufacturing of the vaccine that have put it up to two months behind its initial production schedule. The report comes amid growing anticipation for data from Johnson ...

Please Register

To continue reading, please login or register for full access to our free content
Loadstar subscriber
New Loadstar subscriber REGISTER

Comment on this article


You must be logged in to post a comment.